Stay updated with breaking news from Study May Proceed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn., Jan. 3, 2024...
Company Closes Financing and Prepares to Launch Phase 1b/2a Clinical TrialPITTSBURGH--(BUSINESS WIRE)--#CRS--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a Study May Proceed letter from the U....
Boston (Massachusetts) [US]/ Noida (Uttar Pradesh) [India], December 6 (ANI/PRNewswire): Curadev Pharma, a small molecule drug discovery and development company focused on the generation of novel therapeutics for the treatment of intractable diseases such as cancer has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin a Phase 1 study of its lead STING agonist CRD3874 in advanced/metastatic solid cancers. The study will be performed at a leading US cancer center. Successful clearance of tumors by the immune system requires the action of Type ...
/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...